Arcutis Biotherapeutics Inc (NASDAQ: ARQT) on Friday, plunged -3.15% from the previous trading day, before settling in for the closing price of $13.67. Within the past 52 weeks, ARQT’s price has moved between $5.38 and $16.20.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 379.27% over the last five years. The company achieved an average annual earnings per share of 65.01%. With a float of $102.98 million, this company’s outstanding shares have now reached $117.00 million.
The firm has a total of 296 workers. Let’s measure their productivity. In terms of profitability, gross margin is 89.43%, operating margin of -131.16%, and the pretax margin is -140.72%.
Arcutis Biotherapeutics Inc (ARQT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Arcutis Biotherapeutics Inc is 12.02%, while institutional ownership is 103.72%. The most recent insider transaction that took place on Jan 02 ’25, was worth 146,714. In this transaction Director of this company sold 10,000 shares at a rate of $14.67, taking the stock ownership to the 151,944 shares. Before that another transaction happened on Jan 02 ’25, when Company’s Director proposed sale 10,000 for $14.67, making the entire transaction worth $146,714.
Arcutis Biotherapeutics Inc (ARQT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 65.01% per share during the next fiscal year.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Arcutis Biotherapeutics Inc (ARQT) is currently performing well based on its current performance indicators. A quick ratio of 2.38 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.17.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.26 in the next quarter and is forecasted to reach -0.83 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Analysing the last 5-days average volume posted by the [Arcutis Biotherapeutics Inc, ARQT], we can find that recorded value of 1.91 million was lower than the volume posted last year of 1.93 million. As of the previous 9 days, the stock’s Stochastic %D was 35.80%. Additionally, its Average True Range was 0.96.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 63.77%, which indicates a significant increase from 25.40% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 53.32% in the past 14 days, which was lower than the 63.83% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.20, while its 200-day Moving Average is $10.31. Now, the first resistance to watch is $13.67. This is followed by the second major resistance level at $14.11. The third major resistance level sits at $14.36. If the price goes on to break the first support level at $12.98, it is likely to go to the next support level at $12.73. Now, if the price goes above the second support level, the third support stands at $12.29.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
Market capitalization of the company is 1.55 billion based on 117,045K outstanding shares. Right now, sales total 59,610 K and income totals -262,140 K. The company made 44,760 K in profit during its latest quarter, and -41,540 K in sales during its previous quarter.
